Lumacaftor
 | |
| Systematic (IUPAC) name | |
|---|---|
|
3-{6-{[1-(2,2-Difluoro-1,3-benzodioxol-5-yl)cyclopropanecarbonyl]amino}-3-methylpyridin-2-yl}benzoic acid | |
| Clinical data | |
| Legal status | |
| Legal status |
|
| Identifiers | |
| CAS Number |
936727-05-8  |
| ATC code | None |
| PubChem | CID 16678941 |
| IUPHAR/BPS | 7481 |
| ChemSpider | 17611836 |
| ChEBI |
CHEBI:90951  |
| Chemical data | |
| Formula | C24H18F2N2O5 |
| Molar mass | 452.407 g/mol |
| |
| |
| (what is this?) (verify) | |
Lumacaftor (VX-809) is a pharmaceutical drug that acts as a chaperone during protein folding and increases the number of CFTR proteins that are trafficked to the cell surface.[1] It is available in a single pill with ivacaftor; the combination, lumacaftor/ivacaftor (brand name Orkambi), is used to treat people with cystic fibrosis who have the F508del mutation in the cystic fibrosis transmembrane conductance regulator (CFTR), the defective protein that causes the disease.[2] It was developed by Vertex Pharmaceuticals and the combination was approved by the FDA in 2015.[3] As of 2015 lumacaftor had no medical use on its own.[1]
See also
- Ataluren, targeting premature stop codons
References
- 1 2 Kuk K, Taylor-Cousar JL. Lumacaftor and ivacaftor in the management of patients with cystic fibrosis: current evidence and future prospects. Ther Adv Respir Dis. 2015 Dec;9(6):313-26. Review. PMID 26416827
- ↑ Lumacaftor label. Last updated July 2015. Check index page here for label updates
- ↑ "Orkambi (lumacaftor and ivacaftor)". CenterWatch. Retrieved 24 March 2016.
| ||||||||||||||||||
This article is issued from Wikipedia - version of the Friday, March 25, 2016. The text is available under the Creative Commons Attribution/Share Alike but additional terms may apply for the media files.